CNGB3 and retinitis pigmentosa: Its neuroprotective effects have been evaluated in patients with dry AMD [95,96], CNGB3-achromatopsia [97], glaucoma [98], retinitis pigmentosa [5,19,99], and macular telangiectasia type 2 (MacTel 2) [100].